eligibility_summary
Adults (≥18) with DLBCL (GCB or non-GCB), IPI>2, expected survival ≥3 months, incomplete remission after 2 cycles of R-CHOP/R-CDOP, measurable disease per Lugano 2014, ECOG 0–1, adequate marrow, renal, and hepatic function. Exclude: drug hypersensitivity, uncontrolled illness, major cardiac disease/QTc>480, active HBV/HCV or HIV, other active cancers, CNS lymphoma, pregnancy/lactation/no contraception, inability to consent, investigator-deemed unsuitable.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT05990985 tests RCMOP sequential therapy (rituximab, cyclophosphamide, mitoxantrone liposome, vincristine, prednisolone) as first-line treatment for intermediate/high-risk DLBCL patients with incomplete remission after initial R-CHOP/R-CDOP. Drug types and mechanisms: Rituximab—anti-CD20 monoclonal antibody, depletes CD20+ B cells via ADCC, complement, and apoptosis. Cyclophosphamide—alkylating agent, DNA crosslinking. Mitoxantrone liposome—anthracenedione/topoisomerase II inhibitor, DNA intercalation and strand breaks. Vincristine—vinca alkaloid, inhibits microtubule polymerization (mitotic arrest). Prednisolone—glucocorticoid, induces lymphocyte apoptosis. Targets: malignant CD20+ B cells, DNA replication/repair, topoisomerase II, microtubules/mitotic spindle, glucocorticoid receptor pathways.